EUVIMEDEUVIMED entdecken
Crossref

Topical pharmacologic management of post-botulinum toxin-induced blepharoptosis: a narrative review of evidence and clinical applications

Chaiyarin Milinjaroonpong, Pongsiri Koonngam

Aesthetic Medicine · 30.09.2026

DOI: 10.57662/am.2026.18373 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Aesthetic Medicine, erschienen am 30.09.2026. Verfasst von Chaiyarin Milinjaroonpong und 1 weiteren Autor:innen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Botulinum toxin type A (BoNT-A) is widely used for cosmetic and therapeutic purposes, yet post-injection blepharoptosis remains a distressing complication for both patients and clinicians. While spontaneous resolution typically occurs within weeks, pharmacologic management - particularly with topical agents - offers an evidence-based means to expedite recovery and alleviate symptoms. This review aims to summarize the pharmacologic management of post–BoNT-A–induced blepharoptosis, focusing on mechanisms, efficacy, safety, and practical clinical application.

Methods

Literature was identified through targeted database searches including PubMed, Scopus, and Google Scholar, focusing on oxymetazoline, apraclonidine, phenylephrine, brimonidine, and pyridostigmine. Each agent’s mechanism, receptor specificity, dosage, onset, duration, and safety profile are discussed.

Results

Clinical outcomes from case reports, trials, and expert consensus are summarized, highlighting variable efficacy and limited high-quality evidence. Oxymetazoline 0.1% has the strongest evidence, demonstrating consistent improvement in upper eyelid elevation via -adrenergic receptor–mediated Müller’s muscle contraction. Apraclonidine 0.5% remains a commonly recommended option despite potential tachyphylaxis. Phenylephrine is effective but may cause systemic side effects and rebound hyperemia. Brimonidine and pyridostigmine have niche roles with less robust data. Topical pharmacologic agents are generally well tolerated; however, the literature underscores the need for randomized controlled trials to determine optimal selection, dosing, and long-term safety.

Conclusions

This review provides a practical reference for clinicians in aesthetic and ophthalmic practice, emphasizing evidence-based drug choice and application.

Schlagwörter

botulinum toxin type Aptosispost-injection complicationsoxymetazolineapraclonidinephenylephrinebrimonidinepyridostigmineMüller's musclealpha-adrenergic agonists

Zitieren

APA

Milinjaroonpong, C., & Koonngam, P. (2026). Topical pharmacologic management of post-botulinum toxin-induced blepharoptosis: a narrative review of evidence and clinical applications. Aesthetic Medicine. https://doi.org/10.57662/am.2026.18373

Vancouver

Milinjaroonpong C, Koonngam P. Topical pharmacologic management of post-botulinum toxin-induced blepharoptosis: a narrative review of evidence and clinical applications. Aesthetic Medicine. 2026. doi:10.57662/am.2026.18373

BibTeX
@article{Milinjaroonpong2026,
  author = {Milinjaroonpong, Chaiyarin and Koonngam, Pongsiri},
  title = {Topical pharmacologic management of post-botulinum toxin-induced blepharoptosis: a narrative review of evidence and clinical applications},
  journal = {Aesthetic Medicine},
  year = {2026},
  doi = {10.57662/am.2026.18373}
}
Kostenlos starten →